Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, Clene is raising $9,250,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Rob Etherington played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Clene

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. Clene’s clinical program targets neurodegenerative disease to improve cellular bioenergetic function with nanocatalysts. Current Phase 2 studies include treatment of multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease) neurodegenerative diseases with high unmet medical need. This approach may have broad applications across therapeutic areas with impaired bioenergetics.

To learn more about Clene, visit http://clene.com/

Contact:
Rob Etherington, President and Chief Executive Officer
801-676-9695
rob@clene.com
https://www.linkedin.com/in/rob-etherington-431718/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved